BR112022023031A2 - Terapia de combinação para amiloidose por ttr - Google Patents
Terapia de combinação para amiloidose por ttrInfo
- Publication number
- BR112022023031A2 BR112022023031A2 BR112022023031A BR112022023031A BR112022023031A2 BR 112022023031 A2 BR112022023031 A2 BR 112022023031A2 BR 112022023031 A BR112022023031 A BR 112022023031A BR 112022023031 A BR112022023031 A BR 112022023031A BR 112022023031 A2 BR112022023031 A2 BR 112022023031A2
- Authority
- BR
- Brazil
- Prior art keywords
- ttr
- combination therapy
- amyloidosis
- ttr amyloidosis
- attr
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20174177 | 2020-05-12 | ||
| PCT/EP2021/062706 WO2021228987A1 (en) | 2020-05-12 | 2021-05-12 | Combination therapy for ttr amyloidosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022023031A2 true BR112022023031A2 (pt) | 2022-12-20 |
Family
ID=70682637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022023031A BR112022023031A2 (pt) | 2020-05-12 | 2021-05-12 | Terapia de combinação para amiloidose por ttr |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230183329A1 (https=) |
| EP (1) | EP4149972A1 (https=) |
| JP (1) | JP7834032B2 (https=) |
| KR (1) | KR20230009950A (https=) |
| CN (1) | CN115551886A (https=) |
| AU (1) | AU2021272369A1 (https=) |
| BR (1) | BR112022023031A2 (https=) |
| CA (1) | CA3172824A1 (https=) |
| CL (2) | CL2022003141A1 (https=) |
| CO (1) | CO2022017877A2 (https=) |
| IL (1) | IL298135A (https=) |
| MX (1) | MX2022014223A (https=) |
| WO (1) | WO2021228987A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023099788A1 (en) * | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| AU2023382527A1 (en) * | 2022-11-15 | 2025-06-26 | Alexion Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2025104243A1 (en) | 2023-11-15 | 2025-05-22 | Neurimmune Ag | Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2025238147A1 (en) * | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| US10344080B2 (en) * | 2013-12-20 | 2019-07-09 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor |
| EP3101131B1 (en) | 2014-01-29 | 2020-08-19 | KM Biologics Co., Ltd. | Anti-transthyretin humanized antibody |
| EP3981874A1 (en) | 2014-01-29 | 2022-04-13 | KM Biologics Co., Ltd. | Anti-transthyretin human antibody |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2018007923A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| CU24731B1 (es) * | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| CU20200042A7 (es) * | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
-
2021
- 2021-05-12 CN CN202180034796.0A patent/CN115551886A/zh active Pending
- 2021-05-12 AU AU2021272369A patent/AU2021272369A1/en active Pending
- 2021-05-12 MX MX2022014223A patent/MX2022014223A/es unknown
- 2021-05-12 WO PCT/EP2021/062706 patent/WO2021228987A1/en not_active Ceased
- 2021-05-12 JP JP2022568518A patent/JP7834032B2/ja active Active
- 2021-05-12 CA CA3172824A patent/CA3172824A1/en active Pending
- 2021-05-12 BR BR112022023031A patent/BR112022023031A2/pt unknown
- 2021-05-12 US US17/924,496 patent/US20230183329A1/en active Pending
- 2021-05-12 EP EP21724330.2A patent/EP4149972A1/en active Pending
- 2021-05-12 IL IL298135A patent/IL298135A/en unknown
- 2021-05-12 KR KR1020227043263A patent/KR20230009950A/ko active Pending
-
2022
- 2022-11-10 CL CL2022003141A patent/CL2022003141A1/es unknown
- 2022-12-09 CO CONC2022/0017877A patent/CO2022017877A2/es unknown
-
2025
- 2025-04-14 CL CL2025001129A patent/CL2025001129A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022003141A1 (es) | 2023-07-21 |
| WO2021228987A1 (en) | 2021-11-18 |
| EP4149972A1 (en) | 2023-03-22 |
| CL2025001129A1 (es) | 2025-11-28 |
| US20230183329A1 (en) | 2023-06-15 |
| AU2021272369A1 (en) | 2023-01-19 |
| MX2022014223A (es) | 2023-04-14 |
| CO2022017877A2 (es) | 2023-02-27 |
| JP7834032B2 (ja) | 2026-03-23 |
| KR20230009950A (ko) | 2023-01-17 |
| IL298135A (en) | 2023-01-01 |
| JP2023525790A (ja) | 2023-06-19 |
| CA3172824A1 (en) | 2021-11-18 |
| CN115551886A (zh) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023031A2 (pt) | Terapia de combinação para amiloidose por ttr | |
| CL2023002497A1 (es) | Uso de inhibidores de bet como tratamiento para la mielofibrosis | |
| MX2024003373A (es) | Dosis de complejos dirigidos a musculos para el tratamiento de distrofinopatias. | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2014000555A (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| MX2018011102A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| CO2023001561A2 (es) | Combinaciones para el tratamiento de cáncer | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| UY32739A (es) | Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR112019002945A2 (pt) | terapia de combinação para o tratamento de câncer pancreático | |
| BRPI0513168A (pt) | memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia | |
| BR112023018745A2 (pt) | Método para tratar nefropatia por iga com proteína de fusão de taci-fc | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| CL2024001870A1 (es) | Paradigma de tratamiento para una terapia con anticuerpos anti-cd19. | |
| BR112022019914A2 (pt) | Coadministração de mirdametinibe e lifirafenibe para uso no tratamento de cânceres | |
| MX2023004554A (es) | Uso de benzodiazepinas para aumentar la sensibilidad a la psilocibina despues de un regimen cronico de isrs. | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| MX2023015097A (es) | Tratamiento de sintomas asociados a neoplasias mieloproliferativas. | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| BR112022026094A2 (pt) | Usos de um inibidor de hif-2a e lenvatinibe, ou um sal farmaceuticamente aceitável do mesmo, e de uma combinação terapêutica, e, kit | |
| BR112022019518A2 (pt) | Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo |